{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:09:39Z","timestamp":1779908979303,"version":"3.53.1"},"reference-count":38,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Prolonged seizures are life-threatening emergencies associated with significant morbidity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the efficacy and safety of levetiracetam in treating convulsive status epilepticus (CSE) in childhood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data sources and study selections<\/jats:title><jats:p>PubMed, Embase, the Cochrane Central Register of Controlled Trials and Cumulative Index to Nursing and Allied Health Literature were searched from inception up to April 2020. Only randomised controlled trials (RCTs) that included children aged 1\u2009month\u201318 years were assessed. Two reviewers performed data assessment and extraction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data extraction and synthesis<\/jats:title><jats:p>Ten studies out of the 20\u2009637 citations identified were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcomes<\/jats:title><jats:p>Cessation of seizure activities, time to cessation of seizure activities, need for rapid sequence intubation (RSI), intensive care unit (ICU) admission, recurrence of seizures at 24\u2009hours, adverse events and all-cause mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 10 RCTs (n=1907). There was no significant difference in cessation of seizure activities when levetiracetam was compared with phenytoin (risk ratio (RR)=1.03, 95%\u2009CI 0.98 to 1.09), levetiracetam to fosphenytoin (RR=1.16, 95%\u2009CI 1.00 to 1.35) or levetiracetam to valproate (RR=1.10, 95%\u2009CI 0.94 to 1.27). No differences were found in relation to the timing of cessation of seizures for levetiracetam versus phenytoin (mean difference (MD)=\u22120.45, 95%\u2009CI \u22121.83 to 0.93), or levetiracetam versus fosphenytoin (MD=\u22120.70, 95%\u2009CI \u22124.26 to 2.86). There were no significant differences with regard to ICU admissions, adverse events, recurrence of seizure at 24\u2009hours, RSI and all-cause mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Levetiracetam is comparable to phenytoin, fosphenytoin and valproate as a second line treatment of paediatric CSE.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2020-319573","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T21:25:34Z","timestamp":1602797134000},"page":"470-476","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Levetiracetam for convulsive status epilepticus in childhood: systematic review and meta-analysis"],"prefix":"10.1136","volume":"106","author":[{"given":"Ibtihal","family":"Abdelgadir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hamud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodeji","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Pullattayil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K","family":"Akobeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-875X","authenticated-orcid":false,"given":"Colin","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2021042110000600000_106.5.470.1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/adc.79.1.73","article-title":"Status epilepticus: pathophysiology, epidemiology, and outcomes","volume":"79","author":"Scott","year":"1998","journal-title":"Arch Dis Child"},{"key":"2021042110000600000_106.5.470.2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"2021042110000600000_106.5.470.3","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/epi.12426","article-title":"Hippocampal volume loss following childhood convulsive status epilepticus is not limited to prolonged febrile seizures","volume":"54","author":"Yoong","year":"2013","journal-title":"Epilepsia"},{"key":"2021042110000600000_106.5.470.4","unstructured":"Advanced paediatric life support: a practical approach to emergencies (APLS) 6th edition. Available: http:\/\/www.alsg.org\/uk\/Publications [Accessed 1 Apr 2020]."},{"key":"2021042110000600000_106.5.470.5","article-title":"Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children","volume":"1","author":"McTague","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2021042110000600000_106.5.470.6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-Based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"2021042110000600000_106.5.470.7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jped.2017.08.004","article-title":"Management protocols for status epilepticus in the pediatric emergency room: systematic review article","volume":"93(Suppl 1)","author":"Au","year":"2017","journal-title":"J Pediatr"},{"key":"2021042110000600000_106.5.470.8","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00506","article-title":"A comparison of parenteral phenobarbital vs. parenteral phenytoin as second-line management for pediatric convulsive status epilepticus in a resource-limited setting","volume":"10","author":"Burman","year":"2019","journal-title":"Front Neurol"},{"key":"2021042110000600000_106.5.470.9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/ane.12928","article-title":"Why we prefer levetiracetam over phenytoin for treatment of status epilepticus","volume":"137","author":"Zaccara","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"2021042110000600000_106.5.470.10","unstructured":"Higgins JPT , Altman DG , Sterne JAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT , Green S , eds eds. Cochrane Handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http:\/\/www.cochrane-handbook.org\/"},{"key":"2021042110000600000_106.5.470.11","unstructured":"Higgins JPT , Altman DG , Sterne JAC . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT , Green S , eds. Cochrane Handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http:\/\/www.cochrane-handbook.org\/"},{"key":"2021042110000600000_106.5.470.12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2021042110000600000_106.5.470.13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2021042110000600000_106.5.470.14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2021042110000600000_106.5.470.15","unstructured":"Sch\u00fcnemann HJ , Oxman AD , Vist GE , et al . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT , Green S , eds. Cochrane Handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http:\/\/www.cochrane-handbook.org\/"},{"key":"2021042110000600000_106.5.470.16","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (eclipse): a multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"key":"2021042110000600000_106.5.470.17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial","volume":"395","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"key":"2021042110000600000_106.5.470.18","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet"},{"key":"2021042110000600000_106.5.470.19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12098-020-03221-2","article-title":"Clinical effectiveness of levetiracetam compared to fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus","volume":"87","author":"Nalisetty","year":"2020","journal-title":"Indian J Pediatr"},{"key":"2021042110000600000_106.5.470.20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","article-title":"Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an open-label randomized controlled trial","volume":"15","author":"Noureen","year":"2019","journal-title":"J Clin Neurol"},{"key":"2021042110000600000_106.5.470.21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.17511\/ijpr.2018.i04.13","article-title":"Randomized controlled trial of levetiracetam versus fosphenytoin for convulsive status epilepticus in children","volume":"5","author":"Senthil Kumar","year":"2018","journal-title":"Int J Pediatr Res"},{"key":"2021042110000600000_106.5.470.22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.18203\/2349-3291.ijcp20190722","article-title":"Levetiracetam versus phenytoin for treatment of convulsive status epilepticus in pediatric population: a randomized controlled trial","volume":"6","author":"Sharma","year":"2019","journal-title":"Int J Contemp Pediatrics"},{"key":"2021042110000600000_106.5.470.23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/JPN.JPN_126_17","article-title":"IV levetiracetam versus IV phenytoin in childhood seizures: a randomized controlled trial","volume":"13","author":"Singh","year":"2018","journal-title":"J Pediatr Neurosci"},{"key":"2021042110000600000_106.5.470.24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13312-020-1755-4","article-title":"Comparison of phenytoin, valproate and levetiracetam in pediatric convulsive status epilepticus: a randomized double-blind controlled clinical trial","volume":"57","author":"Vignesh","year":"2020","journal-title":"Indian Pediatr"},{"key":"2021042110000600000_106.5.470.25","first-page":"67","article-title":"Levetiracetam versus phenytoin in children with status epilepticus","volume":"8","author":"Wani","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"2021042110000600000_106.5.470.26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00415-011-6227-2","article-title":"Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study","volume":"259","author":"Misra","year":"2012","journal-title":"J Neurol"},{"key":"2021042110000600000_106.5.470.27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1385\/NCC:3:2:161","article-title":"Phenytoin poisoning","volume":"3","author":"Craig","year":"2005","journal-title":"Neurocrit Care"},{"key":"2021042110000600000_106.5.470.28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1059-1311(02)00338-2","article-title":"Adverse events associated with intravenous phenytoin in children: a prospective study","volume":"12","author":"Appleton","year":"2003","journal-title":"Seizure"},{"key":"2021042110000600000_106.5.470.29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2020.03.002","article-title":"Levetiracetam versus phenytoin for the treatment of established status epilepticus: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Li","year":"2020","journal-title":"Seizure"},{"key":"2021042110000600000_106.5.470.30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2019.11.007","article-title":"Therapeutic effect of intravenous levetiracetam in status epilepticus: a meta-analysis and systematic review","volume":"74","author":"Chu","year":"2020","journal-title":"Seizure"},{"key":"2021042110000600000_106.5.470.31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1474-4422(06)70546-4","article-title":"Outcome of paediatric convulsive status epilepticus: a systematic review","volume":"5","author":"Raspall-Chaure","year":"2006","journal-title":"Lancet Neurol"},{"key":"2021042110000600000_106.5.470.32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.seizure.2013.12.007","article-title":"The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies","volume":"23","author":"Yasiry","year":"2014","journal-title":"Seizure"},{"key":"2021042110000600000_106.5.470.33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12028-012-9711-3","article-title":"Practice variations in the management of status epilepticus","volume":"17","author":"Cook","year":"2012","journal-title":"Neurocrit Care"},{"key":"2021042110000600000_106.5.470.34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"key":"2021042110000600000_106.5.470.35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"2021042110000600000_106.5.470.36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(06)69043-0","article-title":"Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study","volume":"368","author":"Chin","year":"2006","journal-title":"Lancet"},{"key":"2021042110000600000_106.5.470.37","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/01.wnl.0000180959.31355.92","article-title":"Treatment delay and the risk of prolonged status epilepticus","volume":"65","author":"Eriksson","year":"2005","journal-title":"Neurology"},{"key":"2021042110000600000_106.5.470.38","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073808331351","article-title":"Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study","volume":"24","author":"Wheless","year":"2009","journal-title":"J Child Neurol"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2020-319573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T17:19:58Z","timestamp":1619025598000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2020-319573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,4,21]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/archdischild-2020-319573"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2020-319573","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}